Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology

Options for Relapsed or Refractory Mantle Cell Lymphoma

At a Glance

If Mantle Cell Lymphoma (MCL) returns or resists initial treatment, targeted daily pills called BTK inhibitors are the standard option. If the disease stops responding to these drugs, intensive treatments like CAR T-cell therapy or clinical trials offer highly effective alternatives.

If Mantle Cell Lymphoma (MCL) returns after your first treatment (relapsed) or does not respond to it (refractory), there is a wide range of powerful options available. The cornerstone of treatment in this setting is a class of drugs called BTK inhibitors, which are daily pills that block a protein the cancer cells need to survive and multiply [1].

The Evolution of BTK Inhibitors

While ibrutinib was the very first drug in this class, its specific FDA indication for MCL was voluntarily withdrawn in the US in 2023 due to its side effect profile compared to newer alternatives. Today, “second-generation” versions are heavily preferred:

  • Acalabrutinib and Zanubrutinib: These are known as covalent BTK inhibitors [2]. They are preferred because they are more “selective,” meaning they have fewer “off-target” effects on other proteins [3]. This leads to a better safety profile, particularly with much lower risks of heart rhythm issues like atrial fibrillation [4][5].
  • Pirtobrutinib: This is a newer type of non-covalent inhibitor [6]. It is specifically used for patients whose cancer has already progressed while taking acalabrutinib, zanubrutinib, or ibrutinib [6]. Because it binds to the BTK protein in a different way, it can often work even when the other drugs have stopped [7][8].

Combination Therapy: The SYMPATICO Trial

The SYMPATICO trial looked at combining a BTK inhibitor with another targeted drug called venetoclax, which blocks a different survival protein [9]. The study found that patients taking both drugs together stayed in remission significantly longer (31.9 months) compared to those taking the BTK inhibitor alone (22.1 months) [9]. However, this combination can be harder on the bone marrow, often leading to lower levels of infection-fighting white blood cells (neutropenia) [9].

CAR T-Cell Therapy: A Powerful Step

For patients whose MCL has failed BTK inhibitors, CAR T-cell therapy (specifically brexucabtagene autoleucel) offers a potentially life-changing option [10]. This treatment involves extracting your own immune T-cells, “re-engineering” them in a lab to recognize the lymphoma, and infusing them back into your body [10].

  • Success Rate: In the landmark ZUMA-2 trial, the vast majority of patients responded to this therapy, and many saw their cancer disappear completely (complete response) [10][11].
  • Risks: Because it is a very active treatment, it carries two main risks: Cytokine Release Syndrome (CRS) (a severe, flu-like immune reaction) and neurotoxicity (temporary confusion or difficulty speaking) [10][12]. These side effects are serious but are usually manageable by experienced medical teams using medications like anakinra or steroids [13].

The Next Frontier: Bispecific Antibodies

Newer treatments called bispecific antibodies (such as glofitamab or epcoritamab) are currently being heavily studied in clinical trials [1]. These “off-the-shelf” intravenous treatments work by grabbing a cancer cell with one “arm” and an immune cell with the other, bringing them together so the immune system can destroy the cancer [1]. These are showing immense promise, even for patients whose disease has returned after CAR T-cell therapy [14].

Common questions in this guide

What are BTK inhibitors and how do they treat relapsed MCL?
BTK inhibitors are targeted daily pills that block a specific protein the cancer cells need to survive and multiply. Second-generation options like acalabrutinib and zanubrutinib are highly preferred because they are effective and carry a lower risk of heart issues than older drugs.
What are my options if my current BTK inhibitor stops working?
Pirtobrutinib is a newer type of non-covalent BTK inhibitor. It binds to the cancer protein differently, allowing it to often work effectively even after your lymphoma has progressed while on standard BTK inhibitors like acalabrutinib or zanubrutinib.
When is CAR T-cell therapy used for Mantle Cell Lymphoma?
CAR T-cell therapy is a powerful procedure where your own immune cells are extracted, re-engineered in a lab to recognize lymphoma, and infused back into your body. It is generally used after MCL has failed to respond to standard BTK inhibitors.
What are the main side effects of CAR T-cell therapy?
Because it is a highly active immune treatment, it carries risks of Cytokine Release Syndrome (a severe, flu-like reaction) and neurotoxicity (temporary confusion or speaking difficulties). These are serious but typically manageable by experienced medical teams.
What are bispecific antibodies for MCL?
Bispecific antibodies are emerging treatments available in clinical trials. They are given via IV and work by linking a cancer cell directly to an immune cell so your body can destroy the lymphoma. They show strong promise even for patients whose cancer returns after CAR T-cell therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for a second-generation BTK inhibitor like acalabrutinib or zanubrutinib instead of standard chemotherapy?
  2. 2.If my lymphoma progresses on my current BTK inhibitor, should we consider pirtobrutinib or go straight to CAR T-cell therapy?
  3. 3.Given my health history, am I healthy enough to handle the potential side effects of CAR T-cell therapy, like neurotoxicity?
  4. 4.Does the combination of a BTK inhibitor and venetoclax (from the SYMPATICO trial) make sense for my specific situation?
  5. 5.Are there any clinical trials for bispecific antibodies available at this center?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Treatment of relapsed/refractory MCL.

    Silkenstedt E, Dreyling M

    Blood 2025; (145(7)):673-682 doi:10.1182/blood.2023022353.

    PMID: 39059015
  2. 2

    Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.

    Owen C, Berinstein NL, Christofides A, Sehn LH

    Current oncology (Toronto, Ont.) 2019; (26(2)):e233-e240 doi:10.3747/co.26.4345.

    PMID: 31043832
  3. 3

    Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma.

    Cai L, Roos J, Miranda PAP, et al.

    Journal of medical economics 2024; (27(1)):1552-1557 doi:10.1080/13696998.2024.2422227.

    PMID: 39461001
  4. 4

    Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.

    Tam CS, Dimopoulos M, Garcia-Sanz R, et al.

    Blood advances 2022; (6(4)):1296-1308 doi:10.1182/bloodadvances.2021005621.

    PMID: 34724705
  5. 5

    Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.

    Lu J, Do B, Primeaux B

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2025; (31(2)):230-235 doi:10.1177/10781552241232331.

    PMID: 38356268
  6. 6

    Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.

    De SK

    Current medicinal chemistry 2024; (31(30)):4757-4762 doi:10.2174/0109298673251030231004052822.

    PMID: 37818564
  7. 7

    Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

    Wang JF, Wang Y

    Expert review of hematology 2024; (17(10)):651-659 doi:10.1080/17474086.2024.2389993.

    PMID: 39109468
  8. 8

    BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.

    Eyre TA, Shah NN, Dreyling M, et al.

    Future oncology (London, England) 2022; (18(36)):3961-3969 doi:10.2217/fon-2022-0976.

    PMID: 36377973
  9. 9

    Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

    Wang M, Jurczak W, Trneny M, et al.

    The Lancet. Oncology 2025; (26(2)):200-213 doi:10.1016/S1470-2045(24)00682-X.

    PMID: 39914418
  10. 10

    KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

    Wang M, Munoz J, Goy A, et al.

    The New England journal of medicine 2020; (382(14)):1331-1342 doi:10.1056/NEJMoa1914347.

    PMID: 32242358
  11. 11

    CAR T-Cell therapy for the management of mantle cell lymphoma.

    Huang Z, Chavda VP, Bezbaruah R, et al.

    Molecular cancer 2023; (22(1)):67 doi:10.1186/s12943-023-01755-5.

    PMID: 37004047
  12. 12

    Managing Treatment-Emergent Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CAR-T Cell Therapy: A Case-Based Review of the use of Emapalumab.

    Donzelli L, Zullino V, Torelli GF, et al.

    Hematological oncology 2026; (44(1)):e70157 doi:10.1002/hon.70157.

    PMID: 41311365
  13. 13

    CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

    Park JH, Nath K, Devlin SM, et al.

    Nature medicine 2023; (29(7)):1710-1717 doi:10.1038/s41591-023-02404-6.

    PMID: 37400640
  14. 14

    Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.

    Heini AD, Bacher U, Porret N, et al.

    Cells 2022; (11(17)) doi:10.3390/cells11172747.

    PMID: 36078155

This page provides educational information about treatment options for relapsed or refractory Mantle Cell Lymphoma. Always consult your oncologist to determine the safest and most effective therapy for your specific diagnosis.

Get notified when new evidence is published on Mantle cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.